HF
SKYE icon

HRT Financial’s Skye Bioscience SKYE Stock Holding History

HRT Financial’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-27,348
Closed -$20K – 4922
2025
Q4 		$20K Buy
+27,348
New +$39.9K ﹤0.01% 2984
2025
Q3 		– Sell
-20,036
Closed -$83K – 3827
2025
Q2 		$83K Buy
+20,036
New +$41.5K ﹤0.01% 2233

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

HRT Financial's SKYE Position: Q1 2026 in Review

HRT Financial sold out of Skye Bioscience (SKYE) in Q1 2026, closing a stake of 27,348 shares — an estimated $20K sold.

HRT Financial first reported a position in SKYE in Q2 2025 and held it in 2 quarters. The position peaked at $83K in Q2 2025. 39 funds tracked by Wall St. Rank hold SKYE as of Q1 2026.

  • HRT Financial reported no remaining Skye Bioscience position as of Q1 2026 after selling out during the quarter.
  • HRT Financial sold 27,348 Skye Bioscience shares in Q1 2026, an estimated $20K.
  • HRT Financial first reported a position in Skye Bioscience in Q2 2025 and held it in 2 quarters.
  • HRT Financial's Skye Bioscience position peaked at $83K in Q2 2025.
  • 39 funds tracked by Wall St. Rank held Skye Bioscience as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.